Myriad Genetics
About Myriad
Myriad Genetics conducts gene discovery and disease pathway research to identify novel, highly-validated and proprietary targets for human drug discovery and pharmacogenomics. Their strategy is to develop therapeutics in areas of critical need, to address certain of the most pervasive diseases of our time. Alzheimer's disease and cancer are among those for which Myriad has product candidates in human testing.
Product Pipeline for Myriad Genetics
Our drug discovery efforts target cancer, rheumatoid arthritis, acute thrombosis, Alzheimer's disease, HIV/AIDS and other viral diseases. In addition, we are exploring the biology around genes that we believe are involved in a variety of disease areas, including atherosclerosis, chronic pain, chronic obstructive pulmonary disease and sleep disorders.
Flurizan -- Alzheimer's Disease --Flurizan is an anti-inflammatory drug that has lowered the levels of beta-amyloid in animal studies.
Flurizan -- Cancer
About Flurizan -- Flurizan is the pure R-enantiomer form of flurbiprofen - an NSAID (non-steroidal anti-inflammatory drug). Flurizan modulates the signal transduction and transcription activation pathways associated with nuclear factor kappa B (NFkB), a principle transcription factor in the expression of many molecules involved in cell growth/death and inflammation. Pre-clinical studies suggest the possibility Flurizan may be used for the treatment and prevention of a large number of cancers.
More on Myriad Genetics